VIRalliance publications

K Skrabal, S Saragosti, J-L Labernardière, F Barin, F Clavel, and F Mammano. Human Immunodeficiency Virus type1 Variants Isolated from Single Plasma Samples Display a Wide Spectrum of Neutralization Sensitivity. J. Virol. 2005. Accepted, under press.

Bouchonnet F, Dam E, Mammano F, de Soultrait V, Henneré G, Benech H, Clavel F, Hance AJ. Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immu nodificinecy virus type 1 resistance to nucleoside analogues. J Virol. 2005. 79 (2) 812-822.

Vandamme AM, Sonnerborg A, Ait-Khaled M, Albert J, Asjo B, Bacheler L, Banhegyi D, Boucher C, Brun-Vezinet F, Camacho R, Clevenbergh P, Clumeck N, Dedes N, De Luca A, Doerr HW, Faudon JL, Gatti G, Gerstoft J, Hall WW, Hatzakis A, Hellmann N, Horban A, Lundgren JD, Kempf D, Miller M, Miller V, Myers TW, Nielsen C, Opravil M, Palmisano L, Perno CF, Phillips A, Pillay D, Pumarola T, Ruiz L, Salminen M, Schapiro J, Schmidt B, Schmit JC, Schuurman R, Shulse E, Soriano V, Staszewski S, Vella S, Youle M, Ziermann R, Perrin L. Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther. 2004 Dec;9(6):829-48.

Poveda E, Rodés B, Labernardière JL, Benito JM, Toro C, González-Lahoz J, Faudon JL, Clavel F, Schapiro J, Soriano V. Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. J Med Virol. 2004 74(1):21-8.

Skrabal K, Trouplin V, Labrosse B, Obry V, Damond F, Hance AJ, Clavel F, Mammano F” Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations” AIDS. 2003 17(6): 809-14.

Labrosse B, Labernardière JL, Dam E, Trouplin V, Skrabal K, Clavel F, Mammano F."Baseline Susceptibility of Primary Human Immunodeficiency Virus Type 1 to Entry Inhibitors". J. Virol. 2003, 77(2):1610-1613.

Vray M, Meynard JL, Dalban C, Morand-Joubert L, Clavel F, Brun-Vezinet F, Peytavin G, Costagliola D, Girard PM; Narval Trial Group. Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088). Antivir Ther. 2003 8(5): 427-34.

Clevenbergh P., E Cua, Dam E, Durant J, Schmit JC, Boulme R, Cottalorda J, Beyou A, Schapiro JM, Clavel F and Dellamonica P. Prevalence of non nucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients. HIV Clin Trials 2002 Jan-Feb; 3(1): 36-44

Meynard JL, M Vray, L Morand-Joubert, E Race, D Descamps, G Peytavin, S Matheron, C Lamotte, S Guiramand, D Costagliola, F Brun-Vezinet, F Clavel and PM Girard for the Narval Trial Group. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure : a randomized trial. AIDS 2002, 16 :727-736.

Duval X, C Lamotte, E Race, D Descamps, F Damond, F Clavel, C Leport, G Peytavin, JL Vildé . Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir Antimicrob Agents Chemother, 2002, 46-2 ; 570-574

Trouplin, V, F Salvatori, F Cappello, V Obry, A Brelot, N Heveker, M Alizon, G Scarlatti, F Clavel and F Mammano. Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. J Virol 2001, 75 : 251-259.

Race E. Cross-resistance within the protease inhibitor class. Antivir Ther. 2001; 6 Suppl 2:29-36.

Picard V, Angelini E, Maillard A, Race E, Clavel F, Chene G, Ferchal F, Molina JM Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.J Infect Dis. 2001 Sep 15; 184(6): 781-4.

Vandamme AM, Houyez F, Banhegyi D, Clotet B, De Schrijver G, De Smet KA, Hall WW, Harrigan R, Hellmann N, Hertogs K, Holtzer C, Larder B, Pillay D, Race E, Schmit JC, Schuurman R, Schulse E, Sonnerborg A, Miller V. Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up. Antivir Ther. 2001 Mar; 6(1): 21-39.

Masquelier, B, E Race, C Tamalet, D Decamps, J Izopet, C Buffet-Janvresse, A Ruffault, AS Mohammed, J Cottalorda, A Schmuck, V. Calvez, E Dam, H. Fleury, F Brun-Vezinet ; the ANRS AC11 Resistance Study Group. French Agence Nationale de Recherche sur le Sida. Genotypic and phenotypic resistance patterns of HIV-1 variants with insertions or deletions in the reverse transcriptase (RT) : multicenter study of patients treated with RT inhibitors. Antimicrob Agents Chemother 2001Jun; 45(6):1836-1842

The EuroGuidelines Group for HIV Resistance (panel member : F Clavel). Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management : recommendations for the European setting. AIDS 2001, 15 :309-320.

Piketty, C, E. Race, P Castiel, L Belec, G Peytavin, A Si-Mohamed, G Gonzalez-Canali, L Weiss, F Clavel and MD Kazatchine. Phenotypic resistance to protease inhibitors in patients who fail on highly active antiretroviral therapy predicts the outcome at 48 weeks of a five drug combination including ritonavir, saquinavir and efavirenz [letter]. AIDS 2000, 14 :626.

Mammano, F, V Trouplin, V Zennou and F Clavel. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors : virus fitness in the absence and in the presence of drug. J Virol 2000, 74 : 8524-8531.

Clavel F, Race E, Mammano F. HIV drug resistance and viral fitness. Adv Pharmacol. 2000; 49: 41-66.

Piketty, C, E. Race, P Castiel, L Belec, G Peytavin, A Si-Mohamed, G Gonzalez-Canali, L Weiss, F Clavel and MD Kazatchine. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS 1999, 13 : F71-F77.

Yerly, S, L Kaiser, E Race, JP Bru, F Clavel and L Perrin. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999, 354 :729-733.

Race, E, E Dam, V Obry, S Paulous, and F Clavel. Analysis of human immunodeficiency virus type 1 cross-resistance to protease inhibitors in patients failing on combination therapies using a rapid single-cycle recombinant virus assay. AIDS 1999, 13 :2061-2068.

Dulioust, A, S Paulous, L Guillemot, AM Delavalle, F Boue, F Clavel. Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors. J. Virol 1999, 73 :850-854.

Mammano, F, C Petit and F Clavel. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1 : phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol 1998, 72 : 7632-7637.


Abstracts

S Mathiesen, E Dam, B Roge, AL Laursen, J Gerstoft and F Clavel. Long-term foscarnet therapy remodels thymidine analogue mutations and reverses resistance to zidovudine.

XIV International HIV Drug Resistance Workshop. Quebec, 2005, ab 98.

C Piketty, C Chazallon, S Lebel-Binay, A-G Marcelin, V Calvez, L Gérard, J-P Aboulker and F Clavel. Evolution of protease genotypes and phenotypes in patients receiving atazanavir-based salvage therapy- XIV International HIV Drug Resistance Workshop. Quebec, 2005, ab101.

HJ Fleury, TA Toni, NTH Lan, PV Hung, A Deshpande, P Recordon-Pinson, A Cheret, S Lebel-Binay and B Masquelier. Susceptibility to ARVs of CRF01_AE, CRF02_AG and subtype C viruses from naive patients:comparative genotypical and phenotypical data - XIV International HIV Drug Resistance Workshop. Quebec, 2005, ab135.

E Dam, S Lastère, D Descamps, O Launay, X Duval, C Dalban, D Costagliola and F Clavel.

Contribution of gag-protease and RT in fitness changes observed in viruses with multiple resistance. XIV International HIV Drug Resistance Workshop. Quebec, 2005, ab153

S Lastere, V Perrin, E Dam, F Brun-Vezinet and F Mammano Replicative capacity and drug susceptibility of viral clones carrying duplication of the PTAPP motif in wild-type and drug-resistant PR-RT context. XIV International HIV Drug Resistance Workshop. Quebec, 2005, ab 159

B Labrosse, L Morand-Joubert, A Goubard, S Rochas, J L Labernardière, J Pacanowski, J L Meynard, A Hance, F Clavel, and F Mammano. Resistance to Enfuvirtide Proceeds through Repeated Selection of HR1 Mutations in Different Env Quasi-species. Abstract 97 & oral presentation. CROI 2005, Boston, February 2005.

S Lebel-Binay, L Thibaut, E Dam, J L Faudon, Arnaud Chéret, A Hill, and F Clavel. Synergistic Activity of Atazanavir and Saquinavir on Viruses with Low Saquinavir and High Atazanavir Resistance. Abstract & Poster 715. CROI 2005, Boston, February 2005.

Zehava Grossman, M Lorber, L Thibaut, E Shahar, D Torten, I Levy, K Riesenberg, M Chowers, V Istomin, D Averbuch, Z Kra-Oz, S Pollack, S Maayan, J Faudon, J Schapiro, and The Israeli Multi Center AIDS Study Group. Virological Response and Resistance to Lopinavir/Ritonavir in Subtype-C Patients Abstract & Poster 719. CROI 2005, Boston, February 2005.

C Piketty, L Gérard, C Chazallon, V Calvez, F Clavel, AM Taburet, JP Aboulker, PM Girard and the Puzzle II study group. Efficacy and safety of atazanavir / ritonavir when combined to tenofovir in HIV infected patients with multiple treatment failure : Puzzle 2 ANRS 107 Trial. 44th ICAAC Octobre 30 –November 2 Washington USA. 2004

E Poveda, B Rodés, S Lebel-Binay, JL Faudon, A Chéret, V Jimenez and V Soriano. Dynamics of Enfuvirtide Resistance in HIV+ Patients During and After Long-Term Enfuvirtide Salvage Therapy, 44th ICAAC Oct. 30 –Nov. 2 2004, Washington, Ab H-190.

E Poveda, B Rodés, S Lebel-Binay, JL Faudon, V Soriano. Evolution of genotypic and phenotypic resistance to Enfuvirtide in heavily treatment-experienced HIV-positive patients. XV International AIDS Conference, Bangkok, 2004, ab WePeB5738.

JL Labernardière , S Lebel-Binay, JL Faudon, A Holguin, V Soriano and A Chéret. Tropism Determination and Performance of PHENOSCRIPT® HIV-1 Entry Inhibitor Assay. XIII International HIV Drug Resistance Workshop. Tenerife, 2004, ab 127

E Dam, F Bouchonnet, F Clavel, and AJ Hance. Effect of RT resistance mutations on viral replication in hydroxyurea-pretreated cells. XIII International HIV Drug Resistance Workshop. Tenerife, 2004, ab 58

E. Poveda, B. Rhodés, S. Lebel-Binay, J.L. Faudon and V. Soriano. Rapid Development of resistance to Enfuvirtide (T-20) in Heavily Treatment Experienced HIV-Infected Patients. 2nd European HIV Workshop, Rome, 2004 [Abstract 31].

E Dam, S Rochas, JL Faudon, A Chéret, A Hill, F Clavel. Synergistic Activity of Lopinavir and Saquinavir on Protease Inhibitor-Resistant HIV-1. XI CROI, San Francisco 2004 [Abstract 622].

A Barrail, C Droz, L Morand-Joubert, E Dam, C Le Tiec, F Clavel, G Chêne, G Raguin, PM Girard, AM Taburet, and the Puzzle 1 Study Group. Inhibitory quotients as predictors of the virological response to amprenavir in heavily pretreated patients. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2003 [Abstract H-1998].

P Palmer P, E Dam, F Ferchal, E Froguel, J Goguel, JM Molina, E Oksenhendle. V106M and V179D, a novel HIV-1 reverse transcriptase (RT) combination of mutations conferring high level resistance to non nucleoside RT inhibitors. 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, 2003, Antiviral Therapy 8 (suppl 1): S411, 2003.

E Dam, F Clavel. Extending the range of measurable resistance to efavirenz : the effect of combinations of mutations and baseline polymorphisms. XII International HIV drug resitance workshop, Los Cabos, 2003 [Abstract S114].

B. Labrosse, JL. Labernadière, E. Dam, V. Trouplin, F. Clavel and F. Mammano. Susceptibilmity of primary viruses to entry inhibitors. XI Intl HIV drug resistance workshop; Antiviral Ther, Sevilla, 2002, 7 (suppl 1) :110 [abstract 101].

C. Droz, L Morand-Joubert, G. Raguin, AM Taburet, E. Dam, G. Chene and F Clavel. Impact and evolution of resistance in patients treated by a salvage regimen combining amprenavir , lopinavir and ritonavir (the Puzzle1 Study) . XI Intl HIV drug resistance workshop; Antiviral Ther, Sevilla, 2002, 7 (suppl 1) :146 [abstract 134].

Vray M, JL Meynard , C. Dalban, L Morand-Joubert, F Brun-Vezinet, F Clavel, D Costagliola and PM Girard for the ANRS 088 Narval Trial Group. Multivariate logistic regression analysis of factors predictive of the virological response in the NARVAL trial. XI Intl HIV drug resistance workshop; Antiviral Ther, Sevilla, 2002, 7 (suppl 1) :145 [abstract 133].

N. Desire, C. Amiel, V. Schneider, N. Delphin, E. Dam, F. Clavel, JC Nicolasand W. Rozenbaum. An HIV-1 isolate with the mutation G190E and an isertion between codons 100-105 of reverse transcriptase: phenotypic resistance implications. XI Intl HIV drug resistance workshop; Antiviral Ther, Sevilla, 2002, 7 (suppl 1) :47 [abstract 42].

Obry V., Race E., Vray M., Meynard J. L., Morand-Joubert L., Descamps D., Brun-Vezinet F., and F. Clavel for the ANRS 088 NARVAL Study Team.INSERM U552, Paris, France. Hypersusceptibility to Protease Inhibitors Associated with Mutated Proteases at Codons 30 and 88 in Treated Patients. 9th Conference on Retroviruses and Opportunistic Infections, 2002. [abstract 557-T.]

Meynard J, Vray M, Morand-Joubert L, Peytavin G, Brun-Vezinet F, Clavel F, Girard P Impact of Treatment Guided by Phenotypic or Genotypic Resistance Tests on the Response to Antiretroviral Therapy (ART): Final Analysis of the Narval Trial (ANRS 088) The 1st. IAS Conference on HIV Pathogenesis and Treatment , 2001.

Piketty C, A. Trylesinski, A. Hill, G Peytavin, E Race, A Si-Mohamed, F Clavel,and MD Kazatchkine. Plasma drug levels and resistance as predictors of efficacy for the combination including saquinavir ritonavir and efavirenz. Antiviral Ther, Scottsdale, 2001, 6 (suppl 1) :89 [abstract 120]

Miller et al on the behalf of the EuroGuidelines group. Comparison of HIV 1 drug susceptibility (phenotype) results reported by three major laboratories. Antiviral Ther, Scottsdale, 2001, 6 (suppl 1) :129 [abstract 169]

Dam et al. Comparison of HIV-1 resitance phenotypes obtained by two different assay systems Antiviral Ther, Scottsdale, 2001, 6 (suppl 1) :122 [abstract 158]

Dam et al. Definition of clinically relevant cut offs for the ineterpretation of phenotypic data obtained using Phenoscrit. Antiviral Ther, Scottsdale, 2001, 6 (suppl 1) :123 [abstract 159]

Obry et al. The phenoscript drug susceptibility assay is available to successfully test HIV non B subtypes. Antiviral Ther, Scottsdale, 2001, 6 (suppl 1) :127 [abstract 165]

Obry et al. The extent of association between resistance phenotype and treatment response is highly dependent on the drug. Antiviral Ther, Scottsdale, 2001, 6 (suppl 1) :61 [abstract 78]

Duval, X, Race E. , Lamotte, D., Descamps D., Gervais A., Breton G., Longuet P., Clavel F., Peytavin G., Leport C., Vilde J.L. Inhibitory quotient (IQ) and efficacy of amprenavir (APV) – lopinavir (ABT-r) containing HAART in heavily pretreated HIV patient infected patient (pts). 2nd International workshop on Clinical Pharmacology of HIV therapy. 2001[abstract 5.11].

Yerly, S, E Race, S Vora, P Rizzardi, J-P Chauve, M Flepp, P Vernazza, K Boubaker, M Battegay, JB Bru, L Perrin and the Swiss HIV Cohort Study. Peak in the transmission of drug-resistant variants in 1997 is followed by a reflux in Switzerland. Antiviral Ther, Sitges, 2000, 5 (suppl 3) :143 [abstract 185].

Brun-Vezinet, F, E Race, D Descamps, E Dam, F Telles, V Obry, G Collin, M Vray and F Clavel. Differences between genotype and phenotype in the NARVAL trial, ANRS 088. Antiviral Ther, Sitges, 2000, 5 (suppl 3) :78-79 [abstract 100].

Meynard, JL, M Vray, L Morand-Joubert, S Matheron, G Peytavin, F Calvel, F Brun-Vézinet and PM Girard. Impact of treatment guided by phenotypic or genotypic resistance tests on the response to antiretroviral therapy : a randomised trial (NARVAL, ANRS 088). Antiviral Ther, Sitges, 2000, 5 (suppl 3) :67-68 [abstract 85].

Masquelier, B, E Race, C Tamalet, D Decamps, J Izopet, C Buffet-Janvresse, H Fleury, F Brun-Vezinet and the ANRS AC11 Resistance Study Group. Phenotypic NRTI resistance profiles in different rearrangement patterns of the HIV-1 RT. Antiviral Ther, Sitges, 2000, 5 (suppl 3):20-21 [abstract 25].

Clevenberg, P, E Cua, E Dam, J Durant, R Boulme, J Cottalorda, A Beyou, J Schapiro, F Clavel and P Dellamonica. Prevalance of non-nucleoside reverse transcriptase resistance-associated mutations and polymorphisms in antiretroviral-naive or –pretreated patients and effect on non-nucleoside reverse transcriptase-containing treatment efficacy. Antiviral Ther, Sitges, 2000, 5 (suppl 3) :137-138 [abstract 177].

Race, E. PI resistance – a problem with many solutions. 5th International Congress on Drug Therapy in HIV Infection, Glasgow, 2000.

Faye, A, E Race, V Obry, MH Prevot, V Joly, S Matheron, F Damond, E Dam, S Paulous, and F Clavel. Viral fitness in patients with discordant CD4 and plasma HIV RNA evolution following protease inhibitor failure. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999 [abstract 331].

Mammano, F, V Trouplin, V Obry, Fanny Cappello and F Clavel. A rapid phenotypic assay to evaluate the cell tropism of HIV-1 primary isolates. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999.

Race, E, F Ferchal, E Dam, V Picard, A Maillard, V Obry, MN Sombardier, G Chêne, JM Molina and F Clavel. Selection of HIV-1 variants with wide cross-resistance to reverse transcriptase inhibitors during low-level escape to first-line dual nucleoside therapy. Antiviral Ther, San Diego, 1999, 4 (suppl 1) :80-81 [abstract 118].

Duvivier, C, C Katlama, M Mouroux, M Legrand, E Chiesa, L Schneider, H Ait-Mohand, A Agher, A Coutellier, MH Fievet, E Race, F Clavel and V Calvez. GIGHAART : a rescue therapy in HIV patients with multiple failures to HAART. 7th European Conference on Clinical Aspects and Treatment of HIV-Infection, Lisbon, 1999 [abstract 113].

E. RACE, E. DAM, V. OBRY, S. PAULOUS, and F. CLAVEL. Analysis of HIV Phenotypic Cross-Resistance to Protease Inhibitors in Patients Failing on Combination Therapies. 6th Conference on Retroviruses and Opportunistic Infections. 1999[abstract & poster 119].